These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 37199768)
1. A highlight on carbamazepine-induced adverse drug reactions in Saudi Arabia: a retrospective medical records-based study. Sukkarieh HH; Khokhar AA; Bustami RT; Karbani GA; Alturki FA; Alvi SN Naunyn Schmiedebergs Arch Pharmacol; 2023 Nov; 396(11):3177-3182. PubMed ID: 37199768 [TBL] [Abstract][Full Text] [Related]
2. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Ozeki T; Mushiroda T; Yowang A; Takahashi A; Kubo M; Shirakata Y; Ikezawa Z; Iijima M; Shiohara T; Hashimoto K; Kamatani N; Nakamura Y Hum Mol Genet; 2011 Mar; 20(5):1034-41. PubMed ID: 21149285 [TBL] [Abstract][Full Text] [Related]
3. Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population. Mushiroda T; Takahashi Y; Onuma T; Yamamoto Y; Kamei T; Hoshida T; Takeuchi K; Otsuka K; Okazaki M; Watanabe M; Kanemoto K; Oshima T; Watanabe A; Minami S; Saito K; Tanii H; Shimo Y; Hara M; Saitoh S; Kinoshita T; Kato M; Yamada N; Akamatsu N; Fukuchi T; Ishida S; Yasumoto S; Takahashi A; Ozeki T; Furuta T; Saito Y; Izumida N; Kano Y; Shiohara T; Kubo M; JAMA Neurol; 2018 Jul; 75(7):842-849. PubMed ID: 29610831 [TBL] [Abstract][Full Text] [Related]
4. The HLA-B*15:02 polymorphism and Tegretol Chouchi M; Kaabachi W; Tizaoui K; Daghfous R; Aidli SE; Hila L Rev Neurol (Paris); 2018 May; 174(5):278-291. PubMed ID: 29685430 [TBL] [Abstract][Full Text] [Related]
5. HLA-B*40:02 and DRB1*04:03 are risk factors for oxcarbazepine-induced maculopapular eruption. Moon J; Kim TJ; Lim JA; Sunwoo JS; Byun JI; Lee ST; Jung KH; Park KI; Jung KY; Jeon D; Yu KS; Jang IJ; Chu K; Lee SK Epilepsia; 2016 Nov; 57(11):1879-1886. PubMed ID: 27666425 [TBL] [Abstract][Full Text] [Related]
6. Analysis of Adverse Drug Reactions with Carbamazepine and Oxcarbazepine at a Tertiary Care Hospital. Lee JE; Min KR; Kim SH; Kim AH; Kim ST Yonsei Med J; 2020 Oct; 61(10):875-879. PubMed ID: 32975062 [TBL] [Abstract][Full Text] [Related]
7. Next-generation sequencing-based HLA typing reveals the association of HLA-B*46:01:01 and HLA-DRB1*09:01:02 alleles with carbamazepine-induced hypersensitivity reactions in Vietnamese patients with epilepsy. Bui TP; Nguyen LTT; Le PL; Le NTT; Nguyen TD; Van Nguyen L; Van Nguyen AT; Trinh TH Hum Immunol; 2023 Mar; 84(3):186-195. PubMed ID: 36725456 [TBL] [Abstract][Full Text] [Related]
8. HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population. Niihara H; Kakamu T; Fujita Y; Kaneko S; Morita E J Dermatol; 2012 Jul; 39(7):594-601. PubMed ID: 22211527 [TBL] [Abstract][Full Text] [Related]
9. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Ikeda H; Takahashi Y; Yamazaki E; Fujiwara T; Kaniwa N; Saito Y; Aihara M; Kashiwagi M; Muramatsu M Epilepsia; 2010 Feb; 51(2):297-300. PubMed ID: 19694795 [TBL] [Abstract][Full Text] [Related]
10. Do HLA-A markers predict skin-reactions from aromatic antiepileptic drugs in a Norwegian population? A case control study. Shirzadi M; Thorstensen K; Helde G; Moen T; Brodtkorb E Epilepsy Res; 2015 Dec; 118():5-9. PubMed ID: 26555631 [TBL] [Abstract][Full Text] [Related]
11. Association of Human Leukocyte Antigen Alleles with Carbamazepine- or Lamotrigine-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in an Iranian Population: A Case-control Study. Dastgheib L; Rostami F; Gharesi-Fard B; Asadi-Pooya AA; Namjoo S; Tahmasebi F; Hadibarhaghtalab M Iran J Med Sci; 2023 Jan; 48(1):70-76. PubMed ID: 36688194 [TBL] [Abstract][Full Text] [Related]
12. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Kim WJ; Lee JH; Yi J; Cho YJ; Heo K; Lee SH; Kim SW; Kim MK; Kim KH; In Lee B; Lee MG Pharmacogenet Genomics; 2010 Apr; 20(4):249-56. PubMed ID: 20216337 [TBL] [Abstract][Full Text] [Related]
13. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China. Wu XT; Hu FY; An DM; Yan B; Jiang X; Kwan P; Stefan H; Zhou D Epilepsy Behav; 2010 Nov; 19(3):405-8. PubMed ID: 20833111 [TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Rattanavipapong W; Koopitakkajorn T; Praditsitthikorn N; Mahasirimongkol S; Teerawattananon Y Epilepsia; 2013 Sep; 54(9):1628-38. PubMed ID: 23895569 [TBL] [Abstract][Full Text] [Related]
15. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations. Hsiao YH; Hui RC; Wu T; Chang WC; Hsih MS; Yang CH; Ho HC; Chang YG; Chen MJ; Lin JY; Chen DP; Chang PY; Wu TL; Hung SI; Chung WH J Dermatol Sci; 2014 Feb; 73(2):101-9. PubMed ID: 24268988 [TBL] [Abstract][Full Text] [Related]
16. Association of cutaneous adverse drug reactions due to antiepileptic drugs with HLA alleles in a North Indian population. Ihtisham K; Ramanujam B; Srivastava S; Mehra NK; Kaur G; Khanna N; Jain S; Kumar S; Kaul B; Samudrala R; Tripathi M Seizure; 2019 Mar; 66():99-103. PubMed ID: 30826555 [TBL] [Abstract][Full Text] [Related]
17. Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore. Chong KW; Chan DW; Cheung YB; Ching LK; Hie SL; Thomas T; Ling S; Tan EC Arch Dis Child; 2014 Jun; 99(6):581-4. PubMed ID: 24225276 [TBL] [Abstract][Full Text] [Related]
18. Association between human leukocyte antigens and cutaneous adverse drug reactions to antiepileptics and antibiotics in the Iranian population. Mortazavi H; Rostami A; Firooz A; Esmaili N; Ghiasi M; Lajevardi V; Amirzargar AA; Sheykhi I; Khamesipour A; Akhdar M Dermatol Ther; 2022 May; 35(5):e15393. PubMed ID: 35187767 [TBL] [Abstract][Full Text] [Related]
19. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. Powell G; Saunders M; Marson AG Cochrane Database Syst Rev; 2010 Jan; (1):CD007124. PubMed ID: 20091617 [TBL] [Abstract][Full Text] [Related]